[go: up one dir, main page]

EP0565683A1 - Chinoxalin-derivate, mit affinität an die quisqualat-rezeptoren - Google Patents

Chinoxalin-derivate, mit affinität an die quisqualat-rezeptoren

Info

Publication number
EP0565683A1
EP0565683A1 EP92922676A EP92922676A EP0565683A1 EP 0565683 A1 EP0565683 A1 EP 0565683A1 EP 92922676 A EP92922676 A EP 92922676A EP 92922676 A EP92922676 A EP 92922676A EP 0565683 A1 EP0565683 A1 EP 0565683A1
Authority
EP
European Patent Office
Prior art keywords
dioxo
acid
nitro
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92922676A
Other languages
German (de)
English (en)
French (fr)
Inventor
Andreas Huth
Ralph Schmiechen
Ilse Beetz
Ingrid Schumann
Lechoslaw Turski
Peter Andreas LÖSCHMANN
David Norman Stephens
Dieter Seidelmann
Martin Krüger
Dieter Rahtz
Peter Hölscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4135871A external-priority patent/DE4135871A1/de
Application filed by Schering AG filed Critical Schering AG
Publication of EP0565683A1 publication Critical patent/EP0565683A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Definitions

  • the invention relates to quinoxalinedione carboxylic acid and phosphonic acid derivatives, their preparation and use in medicaments.
  • quinxaline derivatives have affinity for the quisqualate receptors and, because of their affinity, are suitable as medicaments for the treatment of diseases of the central nervous system.
  • the compounds according to the invention have the formula I.
  • substituted with R 2 is substituted C 1-12 alkyl, with R 2
  • R 2 is substituted with C 3-7 cycloalkyl, - (CH 2) n -C 6-12 -aryl, which in the aryl radical or
  • Alkyl radical is substituted by R 2 or - (CH 2 ) n -hetaryl which is substituted by R 2 in the hetaryl or alkyl radical,
  • R 5 , R 6 , R 7 and R 8 are the same or different and are hydrogen, halogen, nitro, NR 9 R 10 , NHCOR 11 , SO R 12 , C 3-7 cycloalkyloxy, COR 13 , cyano, CF 3 , C 1-6 alkyl, C 1-4 alkoxy or optionally with cyano, C 1-4 alkyl or
  • R 5 and R 6 or R 7 and R 8 represent a fused-on benzene ring
  • R 2 -CO-R 3 or -PO-XY and R 2 is one or two times the same or different and n is 0, 1, 2, 3, 4 or 5 and
  • R 3 is hydroxy, C 1-6 alkoxy or NR 9 R 10 ,
  • X and Y are the same or different and are hydroxy, C 1-6 alkoxy, C 1-4 alkyl or NR 9 R 10 and
  • R 9 and R 10 are the same or different and are hydrogen, C 1-4 alkyl or together with the nitrogen atom a saturated 5- or
  • R 11 is C 1-6 alkyl or phenyl
  • R 12 is hydrogen, C 1-4 alkyl, NH-, N ⁇ C 1-4 alkyl), and
  • R 13 is hydroxy, C 1-6 alkoxy, C 1-6 alkyl or NR 9 R 10
  • R 1 cannot be carbamoylmethyl, 1-carboxy-1-phenylmethyl or straight-chain C 1-6 alkyl, that is substituted in the 1-position with -COOH or -COO-C 1-6 -alkyl, and if R is straight-chain C 1-6 -alkyl, which is in the 1-position with -COOH or
  • R 6 and / or R 7 or R 6 and R 8 cannot be fluorine, chlorine or bromine and R 4 -R 8 in each case
  • R 6 and R 7 are not methyl or simultaneously
  • R 6 or R 7 are not NO 2 and R 4 -R 8 are each hydrogen.
  • the compounds of general formula I also include the possible tautomeric forms and include the E or Z isomers or, if a chiral center is present, the racemates or enantiomers.
  • the substituents are preferably in the 6- and / or 7-position.
  • the substituent R 2 is one or two times the same or different in any position on the alkyl, alkenyl, alkynyl, cycloalkyl, hetaryl or aryl radical.
  • Alkyl is in each case to be understood as a straight-chain or branched alkyl radical, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl, h ⁇ xyl, heptyl, octyl, nonyl, decyl, C 1-6 alkyl radicals being preferred.
  • alkyl radical such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl, h ⁇ xyl, heptyl, octyl, nonyl, decyl, C 1-6 alkyl radicals being preferred.
  • Alkenyl contains in particular C 2-6 alkenyl radicals, which can be straight-chain or branched, such as 2-propenyl, 2-butenyl,
  • alkynyl radicals are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl with 2-4 carbon atoms.
  • C 3-7 cycloalkyl is in each case cyclopropyl, cyclobutyl, cyclopentyl,
  • Cyclohexyl and cycloheptyl mean especially C 3-5 cycloalkyl.
  • 5- or 6-membered heteroaromatics with 1-3 nitrogen atoms are suitable as the hetaryl radical, for example pyrazole, imidazole, pyrazine, pyridine, pyrimidine, pyridazine, triazine.
  • Halogen means fluorine, chlorine, bromine and iodine.
  • R 9 and R 10 form a saturated heterocycle together with the nitrogen atom, this means, for example, piperidine, pyrrolidine, morpholine, thiomorpholine or piperazine.
  • R 1 is C 1-12 -alkyl and R 2 COR 3 , R 5 -R 8 are in particular substituents such as NO 2 , NR 9 R 10 , NHCOR 11 , SO 2 R 12 , C 3-7 -cycloalkyloxy, COR 13 , Cyano, CF 3 , C 1-4 alkoxy, optionally substituted imidazole or a fused-on benzene ring.
  • Physiologically compatible salts include salts of organic and inorganic bases such as, for example, the readily soluble alkali and alkaline earth metal salts and also N-methylglucamine, dimethylglucamine, ethylglucamine, lysine, 1,6-hexanediamine, ethanolamine, glucosamine, sarcosine, serinol, To understand tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak base, 1-amino-2,3,4-butanetriol.
  • organic and inorganic bases such as, for example, the readily soluble alkali and alkaline earth metal salts and also N-methylglucamine, dimethylglucamine, ethylglucamine, lysine, 1,6-hexanediamine, ethanolamine, glucosamine, sarcosine, serinol, To understand tris-hydroxy-methyl-amino-methane, aminopropan
  • the compounds of the formula I and their physiologically tolerable salts can be used as medicaments because of their affinity for the quisqualate receptors.
  • the compounds according to the invention are suitable for the treatment of diseases which are caused by hyperactivity of excitatory amino acids such as glutamate or aspartate. Since the new compounds act as antagonists of excitatory amino acids and show a high specific affinity for the AMPA receptors by using the radioactively labeled specific agonist (RS) ⁇ -amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) from displace the AMPA receptors, they are particularly suitable for
  • AMPA receptor Treatment of diseases which can be influenced via the receptors of excitatory amino acids, in particular the AMPA receptor, such as, for example, Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, hypoglycemia, psychoses, muscle stiffness,
  • the invention also includes the combination of the compounds according to the invention with dopamine agonists such as lisuride, terguride, bromocriptine, amantadine derivatives, memantine and its derivatives and the compounds described in EP-A-351 352 and the combination with L-DOPA or L-DOPA and Benserazide.
  • dopamine agonists such as lisuride, terguride, bromocriptine, amantadine derivatives, memantine and its derivatives and the compounds described in EP-A-351 352 and the combination with L-DOPA or L-DOPA and Benserazide.
  • the dose of the conventional drug to be administered is reduced and its effect is synergistically increased.
  • the compounds are potent, centrally acting AMPA antagonists. They are therefore suitable for the treatment of illnesses that are associated with a disturbance in the glutamate metabolism. They are particularly suitable for the treatment of cerebral ischemia of various origins, Parkinson's disease and also of the other diseases mentioned in the previous paragraph.
  • the compounds according to the invention are brought into the form of a pharmaceutical preparation which, in addition to the active ingredient for enteral or parenteral administration, has suitable pharmaceutical, organic or inorganic inert carrier materials, such as water, gelatin, gum arabic, milk sugar, starch, Contains magnesium stearate, talc, vegetable oils, polyalkylene glycols etc.
  • the pharmaceutical preparations can be in solid form, for example as tablets, dragees, suppositories, capsules or in liquid form, for example as solutions. Suspensions or emulsions are present. If necessary, they also contain auxiliary substances such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing the osmotic pressure or buffers.
  • Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
  • Surfactant auxiliaries such as salts of bile acids or animal or vegetable phospholipids, but also mixtures thereof and liposomes or their components can also be used as carrier systems.
  • Tablets, coated tablets or capsules with talc and / or hydrocarbon carriers or binders, such as lactose, corn or potato starch, are particularly suitable for oral use. It can also be used in liquid form, for example as juice, to which a sweetener may be added.
  • the dosage of the active ingredients can vary depending on the route of administration, age and weight of the patient, type and severity of the disease to be treated and similar factors.
  • the daily dose is 0.5-1000 mg, preferably 50-200 mg, it being possible for the dose to be administered as a single dose to be administered once or divided into 2 or more daily doses.
  • R 1 , R 5 , R 6 , R 7 and R 8 have the above meaning, with reactive
  • R 4 , R 5 , R 6 , R 7 and R 8 have the above meaning, reacted with R 1 -X to give compounds of the formula I and, if desired, saponifying the ester group or esterifying or amidating the acid group or the
  • U and V are leaving groups and R 11 is hydrogen, cyano or COOC 1-6 alkyl and R 12 is hydrogen or C 1-6 alkyl, converted to an imidazole derivative or separating the isomers or forming the salts.
  • the cyclization of the compounds of formula II with a reactive oxalic acid derivative takes place in one or two stages.
  • the two-stage process is to be regarded as preferred, in which the diamine with an oxalic acid derivative such as the oxal ester half chloride in polar solvents such as dimethylformamide or cyclic or acyclic ethers or halogenated hydrocarbons, for example tetrayhdrofuran, diethyl ether or methylene chloride in the presence of a base such as organic amines, for example triethylamine, pyridine, Hünig -Base or Diethylaminopyridin is implemented.
  • polar solvents such as dimethylformamide or cyclic or acyclic ethers or halogenated hydrocarbons, for example tetrayhdrofuran, diethyl ether or methylene chloride
  • a base such as organic amines, for example triethylamine
  • the subsequent cyclization can be carried out in a basic or acidic manner, but preferably in an acidic environment, and alcohol can be added to the solvent.
  • the substituents R 1 and R 4 are introduced by the customary alkylation methods, by adding the quinoxalinedione with R 1 - or R 4 ' -X, where X is tosylate, mesylate or in particular triflate or halogen, in the presence of bases at room temperature or higher Temperature in aprotic solvents.
  • the anion can also be generated before R 1 - or R 4 ' X are added.
  • bases are, for example
  • Alkali compounds such as potassium carbonate, sodium hydroxide, alkali alcoholates and particularly suitable metal hydrides such as sodium hydride.
  • the alkali compounds can possibly also be reacted under phase transfer conditions. You get mixtures of compounds with the
  • Suitable solvents for the reaction are aprotic polar solvents such as dimethylformamide, N-methylpyrrolidone but also cyclic ethers such as dioxane or tetrahydrofuran. If in process variant b) the reaction is carried out with 2 mol R -X under otherwise analogous reaction conditions, the substituents R 1 and R 4 are introduced simultaneously.
  • the subsequent saponification of an ester group can be carried out in a basic or, preferably, acidic manner by hydrolysing at elevated temperature to the boiling point of the reaction mixture in the presence of acids such as high concentrated aqueous hydrochloric acid in solvents such as trifluoroacetic acid or alcohols.
  • acids such as high concentrated aqueous hydrochloric acid in solvents such as trifluoroacetic acid or alcohols.
  • Phosphonic acid esters are preferably hydrolyzed by heating in highly concentrated aqueous acids such as concentrated hydrochloric acid or by treatment with trimethylsilyl bromide and subsequent treatment with water.
  • esterification of the carboxylic acid or phosphonic acid takes place in a manner known per se with the corresponding alcohol in acid or in the presence of an activated acid derivative.
  • suitable acid derivatives are acid chloride, imidazolide or anhydride.
  • Phosphonic acids can be reacted with orthoesters of the corresponding alcohol.
  • the reaction with the adduct of dicyclohexylcarbodiimide and the corresponding alcohol also leads to the ester.
  • Methyl esters can be prepared by reaction with diazomethane.
  • amidation takes place on the free acids or on their reactive derivatives such as acid chlorides, mixed anhydrides, imidazolides or azides by reaction with the corresponding amines at room temperature.
  • the nitro group is reduced to the amino group catalytically in polar solvents at room temperature or elevated temperature below Hydrogen pressure.
  • Metals such as Raney nickel or noble metal catalysts such as palladium or platinum are optionally present as catalysts
  • Suitable for carriers instead of hydrogen, ammonium formate can also be used in a known manner.
  • Reducing agents such as tin (II) chloride or titanium (III) chloride can be used as well as complex metal hydrides, possibly in the presence of heavy metal salts. It may be advantageous to introduce the ester group before the reduction.
  • alkylation can be carried out using alkyl halides, for example, using customary methods. Reductive amination with an aldehyde and reducing agents such as sodium cyanoborohydride is also possible.
  • the acylation takes place according to the known methods. For example, it is reacted in an aqueous medium in the presence of a base with the corresponding acid anhydrides or acid halides.
  • the cyano group can be introduced using the Sandmeyer reaction; for example, the diazonium salts formed as intermediates from the amino compounds with nitrites can be reacted with cyanides in the presence of Cu-I cyanide or with K 2 Ni (CN) 4 .
  • the introduction of the halogens chlorine, bromine or iodine via the amino group cannot be aqueous or aqueous; for example, according to Sandmeyer, aqueous, by reacting the diazonium salts formed intermediately with nitrites with Cu (I) chloride or Cu (I) bromide in the presence of the corresponding acid, hydrochloric acid or hydrobromic acid, or with potassium iodide.
  • the hydrochloride is reacted in non-aqueous manner in a known manner with i-amyl nitrite and, for example, methylene iodide or bromoform in aprotic solvents such as dimethylformamide.
  • Fluorine can be introduced, for example, through the Balz-Schiemann reaction of diazonium tetrafluoroborate.
  • the reaction of the amino group with 2-azabutadienes of the formula IV to the imidazole derivatives takes place in the presence of acids at temperatures from 0 to 150 ° C.
  • the escape groups U and V can be the same or different; C 1-3 dialkylamines, such as dimethyl,
  • the reaction is carried out, for example, in such a way that the amine derivative and the azadiene are initially in an organic acid, such as, for example, formic acid, acetic acid, propionic acid or trifluoroacetic acid
  • organic acid such as, for example, formic acid, acetic acid, propionic acid or trifluoroacetic acid
  • Reaction mixture (up to about 120 ° C) is heated.
  • the acid can be used both as a reactant and as
  • solvents such as alcohols, ethers, ketones, esters such as ethyl acetate, hydrocarbons such as toluene or halogenated hydrocarbons such as carbon tetrachloride can also be added.
  • the amount of acid can be varied within wide limits, but is used in excess. A 3-10-fold excess of acid, based on the amine and the azadiene, is preferably selected.
  • the isomer mixtures can be converted into diastereomers such as e.g. by conventional methods such as crystallization, chromatography or conversion. Salt formation can be separated into the enantiomers or E / Z isomers.
  • the salts are prepared in a customary manner by adding a solution of the compound of the formula I with the equivalent amount or an excess of an alkali metal or alkaline earth metal compound, which is optionally in solution, and separating off the precipitate or working up the solution in a conventional manner.
  • the compounds of formula II can be prepared by preparing 2,4-dinitroarylamines according to the Sanger method, in that o-halo-nitroaromatics, preferably o-fluoro-nitroaromatics such as dinitrofluorobenzene in aqueous solution with amino acid derivatives in the presence of a base like sodium carbonate or Sodium bicarbonate at temperatures between 0 ° C to reflux and then reduced.
  • o-halo-nitroaromatics preferably o-fluoro-nitroaromatics such as dinitrofluorobenzene in aqueous solution with amino acid derivatives in the presence of a base like sodium carbonate or Sodium bicarbonate at temperatures between 0 ° C to reflux and then reduced.
  • This reaction can also be applied to other substituted 2-nitrohalogen compounds.
  • Diarylamino compounds can also be obtained by Ulimann's reaction of dinitrochlorobenzene with an aromatic amine.
  • High-boiling solvents such as dimethylform
  • Enantiomer separation can be carried out on the final stage or in the intermediate stages by optically active auxiliary bases such as e.g. Brucine or 1-phenethylamine take place or also by chromatography over optically active carrier materials.
  • optically active auxiliary bases such as e.g. Brucine or 1-phenethylamine take place or also by chromatography over optically active carrier materials.
  • the enantiomers can also be synthesized
  • Aminoethylphoshonic acid added dropwise in 10 ml of water and 600 mg of sodium carbonate. The mixture is stirred at temperature for 1.5 hours. After the ethanol has been distilled off, the mixture is extracted against acetic acid. The aqueous phase is mixed with 200 mg of imidazole and heated to 110 ° C. for 2 hours. Then another 200 mg of imidazole are added and the mixture is heated to 110 ° C. for 2 hours. It is acidified with 4N hydrochloric acid, suctioned off from the undissolved and the filtrate washed with ethyl acetate. The aqueous phase is concentrated and boiled with ethanol.
  • the hydrochloride is placed well dried in 10 ml of dimethylformamide and 4 ml of methylene iodide and 0.6 ml of i-amyl nitrite are added in succession. After 2 hours at 80 ° C bath temperature, everything has dissolved. It is concentrated in vacuo at the Kugelrohr and the residue is silanized

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP92922676A 1991-10-26 1992-10-25 Chinoxalin-derivate, mit affinität an die quisqualat-rezeptoren Withdrawn EP0565683A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4135871A DE4135871A1 (de) 1991-10-26 1991-10-26 Chinoxalinderivate, deren herstellung und verwendung in arzneimitteln
DE4135871 1991-10-26
DE4224200 1992-07-17
DE4224200 1992-07-17

Publications (1)

Publication Number Publication Date
EP0565683A1 true EP0565683A1 (de) 1993-10-20

Family

ID=25908683

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92922676A Withdrawn EP0565683A1 (de) 1991-10-26 1992-10-25 Chinoxalin-derivate, mit affinität an die quisqualat-rezeptoren

Country Status (17)

Country Link
EP (1) EP0565683A1 (sk)
JP (1) JP3258008B2 (sk)
KR (1) KR100262371B1 (sk)
CN (1) CN1038840C (sk)
AU (1) AU664212B2 (sk)
CA (1) CA2099270A1 (sk)
CZ (1) CZ286351B6 (sk)
FI (1) FI932959A (sk)
HU (1) HUT64756A (sk)
IL (1) IL103538A (sk)
NO (1) NO304693B1 (sk)
NZ (1) NZ244896A (sk)
PL (1) PL171125B1 (sk)
PT (1) PT101004B (sk)
RU (1) RU2117663C1 (sk)
SK (1) SK281518B6 (sk)
WO (1) WO1993008173A1 (sk)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
ATE404201T1 (de) * 1992-06-22 2008-08-15 Univ California Glycinrezeptorantagonisten und ihre verwendung
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE4314592A1 (de) * 1993-04-28 1994-11-03 Schering Ag Benzo(f)chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4428152A1 (de) * 1994-06-22 1996-01-04 Basf Ag Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
CN1067387C (zh) * 1994-09-27 2001-06-20 山之内制药株式会社 1,2,3,4－四氢喹喔啉二酮衍生物
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DE19521058A1 (de) * 1995-06-09 1996-12-12 Basf Ag Verfahren zur Herstellung von Aromaten enthaltenden Polyetherpolyolen
DE19545251A1 (de) * 1995-11-24 1997-05-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
DE19624808A1 (de) 1996-06-21 1998-01-02 Basf Ag Pyrrolylchinoxalindione, ihre Herstellung und Verwendung
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
FR2769309B1 (fr) 1997-10-08 2001-06-15 Oreal Composition de teinture d'oxydation des fibres keratiniques comprenant un derive d'aminoacide en tant que base d'oxydation et nouveaux derives d'aminoacides
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118982A1 (en) * 1983-02-01 1984-09-19 Sumitomo Chemical Company, Limited Organic phosphorous quinoxalinone and their production and use
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK69790D0 (da) * 1990-03-16 1990-03-16 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling af anvendelse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9308173A1 *

Also Published As

Publication number Publication date
CN1038840C (zh) 1998-06-24
HUT64756A (en) 1994-02-28
NO932344L (no) 1993-06-25
CZ286351B6 (cs) 2000-03-15
PT101004B (pt) 1999-10-29
AU664212B2 (en) 1995-11-09
KR100262371B1 (ko) 2000-08-01
KR930703271A (ko) 1993-11-29
FI932959A0 (fi) 1993-06-24
CA2099270A1 (en) 1993-04-27
NO932344D0 (no) 1993-06-25
PL299929A1 (en) 1994-04-05
NZ244896A (en) 1995-07-26
JPH06503583A (ja) 1994-04-21
IL103538A0 (en) 1993-03-15
WO1993008173A1 (de) 1993-04-29
IL103538A (en) 2001-07-24
JP3258008B2 (ja) 2002-02-18
NO304693B1 (no) 1999-02-01
CN1072929A (zh) 1993-06-09
PL171125B1 (pl) 1997-03-28
AU2889492A (en) 1993-05-21
HU9301877D0 (en) 1993-09-28
SK72793A3 (en) 1993-10-06
PT101004A (pt) 1994-01-31
RU2117663C1 (ru) 1998-08-20
CZ138793A3 (en) 1994-01-19
FI932959A (fi) 1993-06-24
SK281518B6 (sk) 2001-04-09

Similar Documents

Publication Publication Date Title
EP0565683A1 (de) Chinoxalin-derivate, mit affinität an die quisqualat-rezeptoren
DE3888093T2 (de) Chinoxalinverbindungen und deren Herstellung und Verwendung.
US5955461A (en) Quinoxalinedione derivatives, their production and use in pharmaceutical agents
EP0888313B1 (de) 2,3-benzodiazepinderivate und deren verwendung als ampa-rezeptoren-hemmer
DE4439493A1 (de) Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
WO1996012724A1 (de) Neue chinoxalindionderivate, deren herstellung und verwendung in arzneimitteln
US6288065B1 (en) Quinoxaline-carboxylic acid derivatives
EP0696289B1 (de) Benzo[f]chinoxalindionderivative, deren herstellung und verwendung in arzneimitteln
US6136805A (en) Quinoxaline dione derivatives, their production and their use in medicaments
DE4135871A1 (de) Chinoxalinderivate, deren herstellung und verwendung in arzneimitteln
DE4314593A1 (de) Pyrido(1,2,3-de)chinoxalinderivate, Verfahren zu deren Herstellung und ihre Verwendung von Arzneimitteln
DE4314591A1 (de) Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
EP0993461A1 (de) Chinoxalindionderivate als ampa-rezeptor-antagonisten
DE4344486A1 (de) Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930524

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL SE

17Q First examination report despatched

Effective date: 19961111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020725